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Abstract
The abundance of Th2 cells in both the airways and circulation associates with asthma
severity. Activation of CRTh2 expressed by Th2 cells mediates production of Th2 cytokines
and inhibits apoptosis. Glucocorticosteroid effects occur through suppression of Th2
cytokines and induction of apoptosis. However, recent evidence shows that the total daily
dose of inhaled glucocorticosteroids was positively correlated with the percentage of
circulating Th2 cells. As such, we chose to examine regulation of Th2 cells by
glucocorticosteroids. We used CCRF-CEM cells as a Th2 cell model and in vitro
differentiated primary Th2 cells to study the effect of dexamethasone. Low dose
dexamethasone treatment reduced IL-13 but surprisingly increased CRTh2, while only high
dose induced apoptosis. Interestingly, T cell activation reduced glucocorticosteroid receptor
signaling genes FKBP5 and GR transcript levels. Our results suggest that
glucocorticosteroids at insufficient doses to trigger apoptosis may sustain CRTh2 + Th2 cells
and thereby maintain inflammation.
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Chapter 1 : Introduction

1

Overview

Asthma is a chronic inflammatory disease of the airways that affects over 3 million
Canadians (8% of the population) over the age of 12 [1]. Asthma is a growing problem as it
is expected to affect over 100 million people worldwide by the year 2025 [1]. Although most
types of asthma are well controlled by medication, asthma has an annual cost to our
healthcare system of 600 million dollars [1]. The majority of the asthma related healthcare
costs occur from patients suffering from severe difficult-to-treat asthma [2]. The
pathogenesis of severe forms of asthma is considered largely related to type 2 inflammation.
The inflammation in asthma patients influences response to glucocorticosteroid (GC), the
main anti-inflammatory medication for asthma [2]. Indeed, much research has examined the
question of why severe asthmatics exhibit persistent inflammation and overall poor control of
their disease despite taking the highest doses of GC [2]. As such, this study focused on
understanding how GCs influence Th2 cells, a T lymphocyte subset elevated in severe
asthma [3, 4].

1.1

Asthma

Asthma patients present clinically with symptoms such as wheezing, shortness of breath, and
chest tightness [5]. Diagnosis of asthma is based primarily on symptoms and reversible
airflow obstruction [5]. Asthma diagnosis can be determined by objective measures such as
forced expiratory volume in one second (FEV1) [6]. A spirometer is commonly used to
assess lung function by measuring changes in the volume of air inhaled and exhaled [5, 6].
Asthma is classified as an obstructive lung disease due to the narrowing of the airways [5].
Thus, asthma patients often have difficulty exhaling air at a normal rate. FEV 1 assesses lung
function by determining the maximum volume of air exhaled in one second [6]. FEV 1 values
are represented as percent predicted, which compares measured FEV1 values relative to
expected FEV1 based on height, sex, race and age [6]. An FEV1 of 80% of the percent
predicted is considered normal [5, 6]. Asthma diagnosis requires performing FEV 1 before
and after administration of a bronchodilator and increases of FEV 1 by 15% and/or 200 mL
identify reversible airflow obstruction [6, 7]. In this circumstance, reversibility of airflow
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obstruction is used to diagnose asthma over the other major chronic disease of the airways,
chronic obstructive pulmonary disease (COPD) which does not show airway reversibility [8].
Another method used to assess variable airflow obstruction is through administration of a
bronchial constrictor [2]. Airway hyper responsiveness (AHR) in asthma is characteristic of
inflammation and smooth muscle cell abnormalities in the airways [9]. Bronchiole
provocation tests (BPTs) are used clinically to assess AHR [9]. Adenosine 5’monophosphates (AMPs) that bind A2B receptors to induce degranulation of mast cells are
used as an indirect BPT [9, 10]. Mast cells release inflammatory mediators such as
histamines, leukotrienes and prostaglandins that act on smooth muscle cells leading to
bronchoconstriction [11]. Thus, AMPs test inflammatory regulation of AHR which is an
indirect measure. Enhanced sensitivity of muscarinic receptors on smooth muscle cells lining
the airways contributes to AHR [12]. The methacholine challenge is a type of direct BPT that
utilizes methacholine which binds muscarinic receptors and induces bronchial constriction
[13]. Thus, asthma patients with enhanced muscarinic receptor sensitivity have bronchioles
that constrict at low doses of methacholine [2]. The concentration that causes FEV 1 to drop
by 20% is considered the provocation concentration (PC20) [2, 7]. Normal airways would
have a PC20 of > 16 mg/ml and an asthmatic patient would have a PC20 of < 8mg/ml [2].
Measuring lung function and reversibility reflects the effect of the inflammatory process but
does not indicate the type of inflammation. The airway inflammation in asthma patients
determines a patients’ response to treatment.

1.1.1

Treatment

Strategies for asthma treatment focus on temporary relief of symptoms and reduction of
chronic inflammation. Inhaled GCs are the mainstay for asthma treatment due to their ability
to reduce airway inflammation [14]. Oral GCs are prescribed in the cases of more severe
forms of asthma despite the high risk for adverse side effects such as osteoporosis, high
blood pressure and obesity with long-term use. Treatment strategies for asthma patients often
involve combinatorial therapy which involve controller medication such as GCs to reduce
inflammation and a reliever medication for temporary relief of symptoms [15]. Reliever
medications include short-acting bronchodilators, such as those that act on β2-adrenergic
receptors on smooth muscle cells that alleviate bronchial constriction [16]. Cysteinyl
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leukotriene (CysLT) receptor antagonists are another family of controller drugs used to target
inflammation mediated symptoms [15]. CysLTs are strong contractile agonists released by
mast cells that are increased in active asthma, thus antagonist treatment blocks potential
bronchoconstriction, edema and mucous production [17]. Advances in our understanding of
asthma have allowed for development of therapeutics with specific immunological targets
[15]. For example, Omalizumab an anti-IgE medication has shown to be successful as an add
on therapy in patients with IgE mediated asthma [18].

1.1.2

Severity

One of the main ways to categorize asthma is based on severity, which is determined based
on symptoms, lung function and response to asthma therapy [2]. The American Thoracic
Society (ATS) defines mild asthma as having symptoms at least 2 times a week but normal
FEV1 (≥ 80%) and requiring no or only low dose inhaled GCs [2, 19]. Moderate asthma is
when patients have daily symptoms accompanied by reduced lung function (FEV 1 between
60-80%), but are taking < 800 µg of inhaled beclomethasone to control their symptoms [2,
19]. Severe asthmatics, on the other hand, have an FEV1 below the normal limit at < 80%
along with persistent symptoms despite taking > 800 µg of beclomethasone a day, and the
need for other controller medications and/or oral GCs [2, 19].

1.1.3

Inflammation

Although clinically asthma is categorized as mild/moderate/severe, these subgroups are not
well associated with a particular type of inflammation [20]. For instance, asthma has been
divided into phenotypes based on the predominance of inflammatory cells such as
eosinophils, helper T cells and neutrophils [21]. The underlying pathology of asthma is
further diversified by etiology [22]. The most common classifications are known as nonallergic and allergic asthma [22, 23]. Non-allergic asthma occurs in the absence of an allergic
reaction and is considered to be due to viral infections, exercise or other primary diseases that
influence bronchial obstruction [23]. Non-allergic asthma is often associated with
neutrophilic and Type 1 cytokine related inflammation [23, 24]. Allergic asthma is defined
by a hypersensitive reaction that occurs in response to an allergen [23, 25] and is commonly
associated with T helper 2 cells (Th2) and eosinophils [23, 26]. Th2 high asthmatic patients
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have been associated with severe asthma [21]. As research continues to uncover the diversity
of asthma this will advance our understanding of its etiology, pathology and treatment [27].

1.2

Development of Allergic Asthma

Allergic asthma is the most common type of asthma and is characterized by elevated blood
and airway eosinophilia and Th2 inflammation [28-30]. It often develops during childhood
following sensitization to an allergen(s) [20]. Both genetic and environmental factors that
influence the developing immune system have been associated with becoming sensitized and
developing allergic asthma [31].

1.2.1

Atopy

Individuals that are genetically predisposed to developing allergic diseases usually become
atopic early in life [32]. Atopy, the state of being sensitized to an antigen, is assessed by a
positive skin prick test or measuring total serum IgE levels [33]. Exposure to LPS from living
on a farm during the first year of life was shown to protect against sensitization, while
environmental pollution has been associated with increased risk of developing asthma [34,
35].

1.2.2

Epithelium

Allergen sensitization develops as a result of an innocuous environmental antigen known as
an allergen activating both the innate and adaptive immune system. The cells of the innate
immune system act as the first line of defense against antigens. In the case of allergic asthma,
the epithelium lining the airways is the first line of contact and its activation initiates an
immune response [36]. The epithelial cells express pattern recognition receptors that are
activated upon allergen exposure to promote allergen sensitization and Th2 mediated
inflammation [37]. Mutations in proteins regulating epithelial integrity such as E-cadherin, αcatenin and ZO-1 have been associated with enhanced allergic sensitization [38]. Loss of
epithelial integrity by epithelial remodeling also makes asthmatics more sensitive to allergen
re-exposure over-time [39]. Even in the absence of any primary epithelial dysfunction,
allergens such as house dust mites (HDM) can cleave tight junctions connecting epithelial
cells to enter the lung mucosal layer [40].
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1.2.3

Antigen Presentation

Antigens in the lung mucosa are recognized by antigen presenting cells (APCs), the cells
which provide the crucial link between the innate and adaptive immune system [41]. The
epithelium secretes factors such as interleukin-33 (IL-33), thymic stromal lymphopoietin
(TSLP) and interleukin-25 (IL-25) that promote maturation of APCs in response to allergen
exposure [37]. APCs such as dendritic cells, macrophages and B cells take up antigens and
process them for presentation to CD4+ T cells [42]. Dendritic cells are the main APCs
responsible for sensitization in allergic asthma [43, 44]. Through phagocytosis or receptor
mediated endocytosis APCs take up the allergen and process a peptide from the allergen
(antigen) into a complex with major histocompatibility complex (MHC) class Ⅱ molecules on
the surface [42]. These APCs migrate to the lymph nodes and present antigens to naive CD4 +
T cells [42].

1.2.4

IgE Production

Interaction of APCs with naïve CD4+ helper T cells (Th) mediates T cell differentiation into
multiple subtypes including Th1, Th2, Th17, induced regulatory T cells (iTreg) and follicular
helper T cells (Tfh) [45]. For many years, Th2 cells were thought to be the primary cells
interacting with B cells to induce isotype switching to IgE [46, 47]. More recently, however,
it has been shown that dendritic cell activated CD4+ T cells first differentiate into Tfh cells
[48]. Tfh cells express Th2 cytokines (IL-4 and/or IL-13) required to induce B cells to form
specialized B cells called plasma cells to produce IgE [49]. Plasma cells migrate to the site of
allergen exposure and produce IgE, which binds to fragment crystallizable Epsilon Receptor
1 (FcɛR1) present on mast cells [50]. This binding of IgE to mast cell represents allergen
sensitization, where an individual is primed to respond to subsequent exposure to allergen.

1.2.5

Th2 Cell Differentiation

Helper T cell differentiation depends on factors such as type of antigen, level of antigen
stimulation, and cytokine environment [45]. Moderate T cell receptor (TCR) cross-linking
favors differentiation to Th2 cells versus high level stimulation, which favors Th1 cell
development [45]. Dendritic cells stimulate naïve CD4 + T cells to differentiate into Th2 cells
through CD3/CD28 crosslinking/co-stimulation, which induces IL-2 and low level IL-4
production from differentiating T cells[51-53]. IL-4 binds to the IL-4R, activating

the
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transcription factor STAT6, which leads to more IL-4 production through autocrine
regulation which promotes Th2 cell differentiation [54]. GATA3 is also upregulated
following TCR activation and both STAT6 and GATA3 remodel the chromatin to open
enhancer regions within genes that enable maintenance of the Th2 phenotype [55]. Despite
this low level of IL-4 production, an external source of IL-4 is likely required to promote full
Th2 differentiation alongside TCR activation, which has been suggested to be basophils
and/or lung tissue residing type 2 innate lymphoid like cells (ILC2s) [56, 57]. A recent study
has suggested that the major source of Th2 cells is not through direct differentiation from
CD4+ T cells but from development of precursor Tfh cells [58]. Dendritic cells and B cells
are required for the development of IL-4 producing Tfh cells [58]. With exposure to HDMs
Tfh cells sustain plasticity to differentiate into type 2 effector helper T cells that can act as
precursors for pathogenic Th2 cells [58]. Inhibiting the production of Tfh cells reduced the
abundance of Th2 cells residing in the lung following HDM exposure [58]. Thus, it appears
that although CD4+ T cells can differentiate into Th2 cells, parallel production from
precursor type 2 Tfh cells is also a source of Th2 cells [48, 58].

1.2.6

Other Avenues to Allergic Sensitization

Though allergic sensitization has been largely considered to be the main driver of type 2
inflammation, recently factors other than allergens have been shown to induce expression of
these cytokines. The epithelium has been shown to produce IL-25 and IL-33 not only in
response to allergen, but also following exposure to virus and pollutants such as cigarette
smoke [59-61]. IL-25 can bind to the IL-25 receptor on naïve T cells to promote Th2
differentiation and induce IL-5 and IL-13 expression [62, 63]. Similarly, IL-33 has been
shown to stimulate basophils to secrete IL-4 and ILC2s to secrete IL-13 and IL-5 [64]. The
IL-4 production by basophils is thought to serve as a source of IL-4 initiating Th2
differentiation [56, 65]. ILC2 secretion of IL-13 has been shown to promote dendritic cell
migration to lymph nodes to promote Th2 differentiation [65]. As such, there is now an
appreciation for the fact that ‘type 2 inflammation’ can develop from allergic sensitization or
following microbial exposures which creates a cytokine milieu that could support subsequent
allergic sensitization.
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1.2.7

Developing Chronic Inflammation

Once an individual is sensitized, reintroduction of the allergen initiates a type 1
hypersensitivity reaction [50]. The early phase of this response is elicited by mast cell
degranulated induced by allergen binding IgE. Mast cell degranulation releases histamines,
chemokines and the lipid mediator prostaglandin D2 (PGD2), which resolves within the 30
minutes [50, 66]. The late phase response, 6 - 24 hours following exposure, is mediated by
inflammatory cell infiltration and amplification of type 2 cytokine expression [67]. During
this response memory T cells develop from re-stimulation by antigens [44].
Four main types of memory T cells develop, stem (TSM), central (TCM), effector (TEM) and
resident memory T cells (TRM) [68]. TSM cells were recently identified in humans as memory
T cells that express FAS, CD122 and naïve markers such as CD45RA [69]. T SM cells have
high proliferative capacity and can differentiate into T CM or TEM cells upon re-stimulation by
antigens [69].

TCM cells have minimal effector function and in response to antigen

stimulation proliferate and differentiate to produce T EM [68]. TEM express CCR4 receptors
required to infiltrate into lung tissue from circulation, while T CM express CD62L, CCR7 and
CD27, which mediate emigration out of tissues and migration back to secondary lymphoid
organs [67, 68]. TCM cells differentiation into TEM cells require the loss of CCR7 expression
to prevent migration into lymph nodes [67]. TEM cells can differentiate into TRM cells that
reside in tissue [70]. TRM cells derived from CD4+ T cells have been shown to secrete IL-2,
tumour necrosis factor α (TNFα) and interferon gamma (IFNγ) in the lungs [71]. Memory T
cells are detrimental for chronic inflammation as re-stimulation causes a much more rapid
and effective response than non-memory T cells, thus for this reason these cells have been
targets for immunotherapy [72].

1.2.8

Type 2 Cytokines

If exposure is continual, inflammation can become chronic with persistent infiltration of
eosinophils and Th2 cells with the secretion of type 2 cytokines IL-4, IL-5 and IL-13 [26].
Each of these cytokines plays an important role in type 2 inflammation. In addition to the
initiation, maintenance and proliferation of Th2 cells, both IL-4 and IL-13 activate the
endothelium to mediate inflammatory cell infiltration [51, 54, 73, 74]. IL-13 also stimulates
epithelial cells to express the MUC5AC gene and produce mucous and smooth muscle cells
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to enhance contractility through elevated calcium signaling [75, 76]. IL-5 regulates
eosinophils [77], stimulating their production in the bone marrow and migration from the
bone marrow to the site of allergen exposure through binding of the IL-5 receptor [78, 79].
Overall IL-4, IL-5 and IL-13 play significant roles in the inflammatory process leading to
narrowing of the airways of asthmatic patients.

1.3

Chemokine Receptor Homologous Molecule Expressed on Th2
cells (CRTh2) is a marker for Th2 cells

In a subtractive RNA hybridization screen of Th2 vs Th1 human cells, Nagata et al showed
the differential expression of a transcript called G protein coupled receptor 44 [80]. Since this
gene has homology with chemokine receptors, they called it chemokine receptor homologous
molecule expressed on Th2 cells (CRTh2) [81]. Their characterization of the receptor
showed surface expression of CRTh2 on Th2, but not Th1 cells, and that CRTh2 + CD4+ T
cells were those that produced IL-4, IL-5 and IL-13 in response to allergen challenge [80,
82]. Despite its name, CRTh2 is also expressed by eosinophils, basophils, ILC2s and was
reported to be present within mast cells [83-85]. However, a subsequent study revealed that
within the CD4+ T helper cell subset, CRTh2 was the most reliable marker of cells
expressing the Th2 cytokine profile [86].

1.3.1

CRTh2+ Th2 cells are elevated in allergic disease

CRTh2+ Th2 cells are increased in patients with atopic dermatitis, nasal mucosa of patients
with allergic rhinitis and the lungs of patients with asthma [4, 87, 88]. Not only are Th2 cells
elevated within the sites of exposure, but also in the circulation of patients with allergic
airway disease [3, 44]. Single nucleotide polymorphisms (SNPs) in CRTh2 have been
associated with higher susceptibility to develop phenotypes of allergic disease, including
allergic asthma, further supporting the importance of CRTh2 in the development of allergic
inflammatory diseases [89-91].

1.3.2

CRTh2+ Th2 cells are central memory T cells

Wang et al identified that Th2 cells are central memory T cells that are sustained in
circulation and form memory against allergens [44]. Memory Th2 cells have been identified
as dominant inflammatory cells involved in the pathogenesis of allergic asthma [44]. The
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majority of memory Th2 cells are at resting state and upon activation form effector memory
cells [68]. Research has identified various pathogenic subsets of memory Th2 cells that
enhance inflammation through secretion of type 2 and non-type 2 cytokines. For example,
IL-5+ memory CRTh2+ Th2 cells have been correlated with blood eosinophils and shown to
regulate AHR [92]. IL-17 producing Th17 cells that are marked by CCR6 expression have
been implicated in steroid resistance, thus may be involved in difficult to treat severe asthma
[93]. CCR6+ CRTh2+ Th2 cells produce both IL-17 and IL-4 and were associated with
recruitment of neutrophils, macrophages, eosinophils at levels superior to Th2 or Th17 cells
independently [94]. The maintenance of memory cells in-vivo provides a challenge in
eliminating inflammation through the reduction of just cytokines and other inflammatory
proteins. While immune memory is beneficial for pathogen elimination, in the case of
allergic disease long lived central memory Th2 cells are one of the main factors mediating
persistence of disease.

1.4

Functions of the CRTh2 Signaling Pathway

CRTh2 is a G-protein coupled receptor (GPCR) that uses Gαi proteins and therefore inhibits
adenylyl cyclase activity [95]. The ligand for CRTh2 is PGD2, released by mast cells
following allergen-IgE crosslinking and is also considered the second D prostanoid receptor
(DP2) [96, 97]. To date, activation of CRTh2 has been shown to regulate Th2 cells by three
main ways, secretion of cytokines, chemotaxis and inhibition of apoptosis (Figure 1) [95, 98,
99].

1.4.1

CRTh2 Mediates Th2 Cytokine Production

In vitro culture of Th2 cells with PGD2, showed that CRTh2 activation results in secretion of
type 2 inflammatory cytokines IL-4, IL-5 and IL-13, but not IL-10 [99]. The mechanism has
been shown to be through Nuclear factor of activated T cells (NFAT) signaling [100]. In
vivo, mice deficient in CRTh2, either through gene knockout (CRTh2-/-) or using CRTh2
antagonists had reduced production of type 2 cytokines in response to allergen sensitization
and challenge [101, 102]. Also, overexpression of lipocalin PGD synthase in mice, the
enzyme responsible for PGD2 production, mediated increase in type 2 cytokines in the
bronchoalveolar lavage (BAL) [103]. CRTh2 mediated release of cytokines is considered to
be through PI3K activation and calcium mobilization [100]. Calcium mobilization in
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response to CRTh2 activation induces calcineurin activity, which dephosphorylates NFAT
allowing for nuclear import leading to transcription of IL-4, IL-5 and IL-13 [100]. The
PGD2-CRTh2 activation of PI3K also activates AKT, which in turn phosphorylates and
inhibits GSK3β [100]. GSK3β can inhibit NFAT through phosphorylation to inhibit NFATs
ability to bind DNA and induce transcription [104].

1.4.2

CRTh2 Mediates Th2 Cell Chemotaxis

CRTh2 also induces Th2 cell chemotaxis by PGD2-mediated PI3K signaling pathway [95].
Overexpression of lipocalin PGD synthase in mice showed increased inflammatory cells in
BAL after allergen challenge [103]. AKT phosphorylation leads to F-actin polymerization
which induces chemotaxis in Th2 cells [100]. This mechanism of PGD 2 mediated chemotaxis
has also been shown in eosinophils and basophils [95]. Interestingly, though, inhibition of
AKT in Th2 cells showed only partial inhibition of chemotaxis. ERK activation may be a
partial regulator of chemotaxis as ERK facilitates CRTh2 mediated chemotaxis of
eosinophils [100, 105].

1.4.3

CRTh2 Inhibits Apoptosis in Th2 cells

PGD2-CRTh2 activation has been shown to inhibit apoptosis in response to IL-2 starvation
and therefore CRTh2 appears to regulate survival [98]. CRTh2 is a GPCR utilizing Gα i
protein, so activation results in influx of Ca2+ from cellular calcium stores [95]. This calcium
influx has been shown to activate PI3K, phosphorylation of AKT and BCL-2 associated
death promotor protein (BAD), which interferes with anti-apoptotic proteins BCL-2 and
BCL-xL [98]. Interference of BCL-2 and BCL-xL would initiate caspase-3 mediated
apoptosis, but AKT signaling downstream of CRTh2 activation inhibits this pathway [98].
Xue et al showed that increasing amounts of PGD2 reduced percentage of Annexin V+ Th2
cells induced by IL-2 starvation [98]. Annexin V staining is an assay for detecting viable
cells undergoing early apoptosis through binding of phosphytidylserines (PS) [106]. During
initiation of apoptosis XRP8 lipid scramblase disrupts the membrane and causes PS to flip
from inner membrane leaflet to outer membrane leaflet [107]. PS can be bound by calcium
dependent protein Annexin V which in combination with nuclear dye 7AAD or propidium
iodide is used to assess early apoptosis and cell death, respectively [106].
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Figure 1: CRTh2 mediated chronic inflammation
Chronic airway inflammation is initiated by allergen surpassing the epithelial barrier and
binding to IgE present on mast cells to cause mast cell degranulation release of PGD 2 (1).
PGD2 binds to inflammatory cells in circulation leading to chemotaxis of these cells into the
lung mucosal layer (2). Th2 cells recruited into the lung mucosa and ILC2s can bind CRTh2
and release type 2 cytokines to enhance inflammation (3). This process occurs chronically
leading to narrowing of the airways.

1.5

Glucocorticosteroid Mechanisms of Action

Since its introduction in 1950, treatment with synthetic GCs has been the main method of
reducing chronic inflammation in asthma [108]. Oral GCs have a broad range of effects on
various tissues leading to obesity, osteoporosis and hypertension which led to the
development of inhaled GCs [108]. Inhaled GCs reduce inflammation in the airways with
minimal systemic absorption. Continued development of more effective inhaled GCs aims to
enhance receptor potency while minimizing off-site systemic effects [108, 109]. Ultimately,
the best approach would be a treatment with no/low side effects and long-lasting effects.
GCs function through binding the GC receptor (GR), which resides in the cytoplasm in a
heterocomplex that includes the chaperone proteins Heat Shock Protein 90 (HSP90) and
FK506 Binding Protein 5 (FKBP5) [110]. Binding of GCs to GR results in a conformational
change and FKBP5 losing affinity for the GR [110]. At this time, FKBP4 then replaces
FKBP5 in the heterocomplex and interacts with dynein motor proteins to transport the GR
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into the nucleus [110, 111]. The ability of GCs to reduce inflammation is mediated through
many mechanisms including binding directly to DNA, affecting mRNA stability and proteinprotein interactions (Figure 2) [14].

1.5.1

Glucocorticosteroid Mediated Transcriptional Regulation

The GR enters the nucleus and dimerizes with itself or other transcription factors to regulate
gene transcription [112]. GR homodimers bind to positive and negative glucocorticoid
response elements (GREs), to activate and repress transcription, respectively [113].
Interestingly, the GR can upregulate expression of proteins involved in the GR signaling
pathway such as GR and FKBP5 [114, 115]. GR represses transcription of pro-inflammatory
genes such as JUN, IL-11 and MAP3K14 [113]. The GR can also activate transcription of
anti-inflammatory genes such as MKP-1, IκB, and GILZ [113, 116, 117]. One of the benefits
of combination therapy with GCs and β agonists is due to the ability of GR to increase
transcription of β2 adrenergic receptor which is reduced in SMCs lining the airways of
asthmatics [118]. Typically, the GR is thought to increase anti-inflammatory gene
transcription and reduce pro-inflammatory gene transcription. However, GCs are also known
to play a key role in T cell maturation and differentiation of T regs through transcriptional upregulation of FOXP3 and glucocorticosteroid induced tumor necrosis factor receptor (GITR)
[119].
Generally, GCs are thought to negatively regulate cytokine expression. Naïve T cells treated
with GCs and CD3 showed a reduction in IL-4 expression [120]. GC treatment in patients
with allergic diseases reduced mRNA expression of type 2 cytokines IL-4, IL-5 and IL-13
[121-124]. The reduction of IL-5 by GCs also reduced eosinophil recruitment [122]. TSLP
contains negative GREs that the GR binds to block transcription [125]. Post-transcriptional
function of the GR also has been shown to reduce mRNA levels by reducing mRNA stability
of IL-4 and TNF-α [126, 127].
However, other studies have reported the contrary. Ramirez et. al. showed that pre-treatment
with GCs enhanced type 2 cytokine expression following T cell activation [128], while
another study showed a positive regulation of cytokines IL-4 and IL-10 when T EM cells were
treated with GC in combination with CD3 stimulation [120]. Therefore, the effect of GC on
cytokines appears to be more complex than simple suppression.
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1.5.2

Glucocorticosteroid Receptor Regulated Protein-Protein Interactions

The anti-inflammatory action also occurs through protein-protein interactions by binding AP1 and NFκB. These transcription factors are up-regulated during T cell activation to promote
inflammatory function of lymphocytes [129]. NFκB is a pro-inflammatory transcription
factor that regulates transcription of pro-inflammatory genes such as cyclooxygenase-2
(COX-2) and TNF-α [130, 131]. NFκB also up-regulates expression of cell adhesion
molecules on lymphocytes to allow lymphocytes into and through the tissues [132]. The GR
can inhibit inflammation by binding directly to NFκB [133]. Even with the GR protein
binding domain mutated, NF-kB was still inhibited by GR activation most likely through
transcriptional regulation of IkB proteins [134]. AP-1 interacts with NFAT to regulate
transcription of cytokines IL-5 and IL-13, while AP-1 can regulate transcription of IL-13
independent of NFAT [135]. AP-1 and GR can mutually inhibit each other, as demonstrated
by studies overexpressing AP-1 and GR.

1.5.3

Glucocorticosteroid Mediated Apoptosis

Apoptosis is dependent on the regulation of BCL family proteins and caspases to induce
death [136]. Caspases- 2,3,6,7,8,9 and 10 all have the potential to be active during apoptosis
depending on whether mode of cell death is triggered intrinsically or extrinsically [137]. For
example, caspase-8 is activated during Fas mediated apoptosis and caspase-9 is activated
during GC-induced apoptosis [138, 139]. Both caspase-8 and caspase-9 cleave procaspase-3,
activating caspase-3 and leading to apoptosis [140].
GC-induced apoptosis is regulated by BCL-2 and BCL-xL expression in cells [141, 142].
Studies show that their reduction leads to apoptosis and BCL-2 and BCL-xL overexpression
has been shown to produce GC resistant T cells [141, 142]. Overexpression of GILZ, a GC
inducible gene, has been shown to be correlated with downregulation of BCL-xL mRNA and
protein [141]. The ability of GCs to induce apoptosis is dependent on transcriptional
upregulation of genes that inhibit anti-apoptotic proteins and downregulation of homeostatic
proteins [141, 143]. Eosinophils showed dose and potency dependent apoptosis in response
to GC treatment [144]. GCs such as hydrocortisone that have lower affinity for the GR were
not able to induce apoptosis [144]. Interestingly, GCs inhibit apoptosis in neutrophils, with
more potent GCs having a greater inhibitory effect [145]. Thus, the ability of GCs to regulate
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apoptosis is dependent on GC potency and dose. GCs have also been shown to inhibit T cell
activation induced apoptosis through up-regulation of MKP-1 and GILZ [146]. T cell
activation induces both AP-1 and NFκB to increase FAS-ligand expression leading to Fasmediated apoptosis [147]. Whether GCs induce or inhibit apoptosis is dependent on the
specific pathways activated, which may explain the ability of GCs to induce apoptosis in
eosinophils and inhibit apoptosis in neutrophils.

Figure 2: Glucocorticosteroid mechanisms of action
GCs binding to the GR leads to the nuclear translocation of the receptor by FKBP4. Once the
receptor is in the nucleus it can homodimerize and bind to DNA to regulate transcription (1),
bind transcription factors to inhibit transcription (2) or reduce mRNA stability (3). GR can
also up-regulate transcription of genes that lead to apoptosis (4).

1.5.4

Glucocorticosteroid Resistance in Asthma

Severe asthmatics are deemed GC resistant because despite taking the highest recommended
dose of GCs these patients show little to no control over their symptoms [2]. One of the
difficulties of identifying mechanisms of GC resistance is the complexity GC- GR signaling
in the various inflammatory cells.
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Previous studies have reported that asthmatic patients have an elevated level of the dominant
negative isoform of the GR beta (GRβ) in peripheral blood mononuclear cells (PBMCs) and
T cells [148, 149]. GRβ binds to GREs and prevents GRα (commonly referred to as GR)
from binding GREs, therefore inhibiting GC-mediated transcription [150]. Work completed
in our laboratory showed that the levels of GRβ in CCRF-CEM cells are very low, ~10,000
times less than GRα, and therefore unlikely to play a major role in T cells. This is a limitation
of the previous studies identifying elevated GRβ in asthmatic patients, as they did not look at
total GR levels [148, 149].
In terms of T cells, GCs have been shown to induce apoptosis in resting T cells, but T cell
activation inhibits GC induced apoptosis through NFAT and AP-1 up-regulation [129, 151].
IL-2, a T cell survival factor has also been shown to inhibit GC-induced apoptosis in T cells
[152, 153]. IL-2 activates the AKT pathway similar to CRTh2 to inhibit GC-induced
apoptosis [154]. IL-2 can also activate STAT5 which can bind and inhibit the GR [155]. T EM
cells unable to produce IL-2 were shown to be more sensitive to GC-induced cell death
[156]. Interestingly, severe asthmatics have also been shown to have higher levels of IL-2
relative to mild/moderate asthmatics [157] and the type 2 cytokine IL-4 was shown to render
Th2 cells GC resistant [74].

1.6

Rationale

Asthma is a disease characterized by chronic inflammation and is mostly controlled by GC
treatment. Allergic asthma, the most common type of asthma is dominated by Th2 cell
inflammation and Th2 dominant phenotypes are associated with the most severe form of
asthma [26]. Severe asthmatic patients despite being prescribed the highest recommended
dose of inhaled GCs and oral GCs show reduced lung function and lack of disease control.
The anti-inflammatory function of GCs is mediated by transcriptional regulation, protein
binding and apoptosis [14].
To better understand why severe asthmatics are GC resistant, research has focused on
identifying unique features of this asthma phenotype. Severe asthmatics have been shown to
have higher abundance of CRTh2 mRNA and higher percentage of CRTh2 + cells in BAL
relative to mild/moderate asthmatics [4]. The percentage of Th2 cells in the circulation was
also higher in severe asthmatics relative to mild/moderate asthmatics [3]. While the
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prevailing thought for GC mechanism of action in asthma is that they reduce Th2 cytokine
production, our laboratory has observed a positive correlation between

the percentage of

Th2 cells in the blood of asthmatic patients and the total daily dose of inhaled GCs [3, 121,
123]. Collectively, these studies suggest there may be a link between the level of Th2 cells
present in the lungs/circulation of asthmatic patients and their response to GC treatment. GCs
could potentially promote Th2 cell phenotype similar to GC promotion of T regs, or promote
survival similar to the phenomenon seen with neutrophils [119, 145]. Understanding the
function of GCs in Th2 cells can provide insight into the method of GC action and potentially
GC resistance.

1.7

Hypothesis & Objectives

1.7.1

Hypothesis

GC function in Th2 cells is dose dependent and varies based on state of T cell activation.

1.7.2

Objectives

Objective 1: To investigate dose dependent effects of GC on pro-inflammatory gene
expression
Daily dose of GCs showed a positive correlation with the percentage of Th2 cells in the
blood of asthmatic patients [3]. Regulation of CRTh2 expression is an important determinant
of Th2 cell function [96]. GCs primarily downregulate transcription of pro-inflammatory
genes, but some studies have indicated otherwise [113, 119]. Understanding how GCs
regulate CRTh2 and IL-13 expression can provide insight into how GCs reduce inflammation
and/or how Th2 cells exhibit GC resistance.
Hypothesis: Low dose GCs regulate CRTh2 and IL-13 expression.
Objective 2: To determine if CRTh2 activation inhibits GC-mediated apoptosis
GCs induce apoptosis in T cells through caspase-3 activation, the same pathway inhibited by
CRTh2 activation [98, 142]. PGD2 and Th2 cells have been shown to be correlated with
asthma severity, indicating that severe asthmatics have the highest level of PGD 2 and Th2
cells [3]. If PGD2 can inhibit GC-induced apoptosis this may be a way that Th2 cells become
GC resistant and results in Th2 cells being sustained in vivo.
Hypothesis: High dose GCs induce apoptosis that is regulated by PGD2.
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Objective 3: To assess how T cell activation influences GR-mediated gene regulation
T cell activation via dendritic cells is a major step in the development of chronic
inflammation in allergic asthma [44]. Interestingly, pathways activated by CD3/CD28
activation are in direct competition with pathways activated by GCs [129, 158]. GCs have
been shown to downregulate secretion of type 2 cytokines by activated T cells [120]. T cell
activation on the other hand has been shown to inhibit GC mediated transcription, but it is
unclear if this also affects genes involved in GR signaling [159]. This can provide further
clarification on the role T cell activation plays in GC resistance.
Hypothesis: T cell activation regulates GR signaling genes.
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Chapter 2

2

Materials and Methods

2.1

Cell Culture

2.1.1

CCRF-CEM cells

An immortalized leukemia CD4+ T cell line CCRF-CEM cells (CCL- 119) was purchased
from American Type Culture Collection (VA, USA). These cells were seeded every 2 days at
0.2x106cells/mL in RPMI 1640 media (Sigma Aldrich, ON, Canada) supplemented with 10%
Fetal Bovine Serum (FBS) (Hyclone Scientific, ON, Canada) and 0.5% Penicillin,
Streptomycin and glutamine (Gibco, ON, Canada).

2.1.2

In Vitro Differentiated Primary Human Th2 cells

For this thesis, experiments were performed on previously frozen in vitro differentiated Th2
cells. Blood was obtained from healthy donors and PBMCs were isolated using Ficoll
histopaque Plus (GE Healthcare, Sweden). CD4 + cells were isolated by negative selection
with a CD4+ cell Isolation Kit II (Miltenyi Biotech, CA, USA). CD4 + T cells were then
differentiated first through activation for 3 days on plate bound anti-CD3 (clone UCHT1,
1μg/mL) and anti-CD28 (clone 37407, 1μg/mL) in the presence of recombinant human
5ng/mL rhIL-2 (R&D Systems, MN, USA), 10-20ng/mL rhIL-4 (R&D Systems, MN, USA),
blocking antibody for IFNγ (polyclonal, 1µg/mL) and IL-12 (Clone C8.6, 1µg/mL). After
activation, cells were proliferated with cytokines (IL-2 and IL-4) and blocking antibodies
(IFNγ and IL-12) for 4 days. Following the 7 days of differentiation, a CRTh2 + selection kit
(Milteny Biotech, CA, USA) was used to enrich CRTh2+ cells using CRTH2-PE conjugated
antibody (Miltenyi Biotech, CA, USA). CRTh2+ cells were sorted using a positive selection
kit (CRTh2+ cell selection kit, Miltenyi Biotech, CA, USA) to obtain a purity of 98%. In
vitro differentiated primary Th2 cells were cultured at 2x10 6 cells/mL in X-Vivo 15 media
(Lonza, MD, USA) supplemented with 10% Fetal Bovine Serum (Wisent, QC, Canada),
0.5% Penicillin, Streptomycin and glutamine (Gibco, ON, Canada) and 5ng/mL of IL-2 (MN,
USA) with cells cycled on plate bound 1μg/mL of αCD3/αCD28 for 3 days or just 5ng/mL
IL-2 for 4 days.
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2.2
2.2.1

Experimental Set-up
Resting Cell Experiments

Experiments were set-up at 0.2x106cells/mL for CCRF-CEM cells and 1.3x106cells/mL with
0-5ng/mL of IL-2 for in vitro differentiated Th2 cells. Cells were treated with 0.01μM-1μM
dexamethasone (Sigma Aldrich, ON, Canada), 13, 14-dihydro-15-keto Prostaglandin D 2
(DK-PGD2) (Caymen Chemicals, MI, USA) and 0.01μM-1 μM of GC antagonist RU486
(Sigma Aldrich, ON, Canada). Cells were harvested by washing with phosphate buffered
saline (PBS) for RNA isolation or PBS flow cytometry activated cell sorting (FACS) (0.5%
bovine serum albumin, 0.1% sodium azide, 3% FBS) for flow cytometry.

2.2.2

Activated Cell Experiments

Experiments were set-up at 0.2x106cells/mL during peak growth phase, day after cells were
seeded. Cells were treated with 0.01μM-1μM dexamethasone (Sigma Aldrich, ON, Canada),
20ng/mL of phorbol 12-myristate 130 acetate (PMA) (Sigma Aldrich, ON, Canada), and
1μM ionomycin (Sigma Aldrich, ON, Canada). Cells were harvested by washing with
Phosphate Buffered Saline (PBS) before pelleting cells for RNA isolation.

2.3
2.3.1

Gene Expression
Quantitative Real Time PCR (qRT-PCR)

Taqman quantitative real-time polymerase chain reaction (qRT-PCR) was used to determine
relative gene expression using complementary DNA (cDNA). This method uses a fluorescent
reporter dye (5’) and a quencher (3’) attached to the reporter probe. As the Taq Polymerase
elongates the template strand it cleaves the reporter from the probe, once separated from the
quencher the probe fluoresces. This florescence is measured and reflects the mRNA
abundance amplified at the end of the assay which is represented by cycle threshold (c t).
To quantify mRNA levels, mRNA was extracted using RNeasy mini plus extraction kit
(Qiagen, ON, Canada). RNA concentrations and quality were assessed using a nano-drop
(Thermo Scientific). RNA samples with a 260/280 and 260/230 ratio greater than 1.8 were
used for complimentary DNA (cDNA) synthesis. cDNA was synthesized using 400ng of
mRNA template, iScript reverse transcriptase (BioRad, CA, USA), and RNAse/DNAse free
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water (Lonza, MD, USA). cDNA synthesis was generated by priming for 5 min (25◦C),
reverse transcription 30 minutes (42◦C) followed by RT inactivation 5 minutes (85◦C).
Resulting cDNA was stored short term at 4◦C and long-term in -20◦C prior to qRT-PCR.
Taqman

gene

expression

(Hs02786624_g1),

CRTh2

assays

(Life

Technologies,

(Hs00173717_m1),

IL-13

CA,

USA)

for

GAPDH

(Hs00174379_m1),

FKBP5

(Hs01561006_m1) and GR (Hs00353740_m1) were used. qRT-PCR reactions contained 2μL
of cDNA, 10μL of Taqman Mastermix (Applied Biosystems, CA, USA) and 7μL of
RNase/DNase free water. Amplification was performed with the full reaction on a CFX 96:
UNG Activation 2 minutes (50◦C), polymerase activation 20 seconds (95◦C), denature within
3 seconds, anneal/extend 30 seconds (60◦C) (for 40 cycles). Data was analyzed using cycle
threshold (Ct) relative to housekeeping gene GAPDH. Fold increase relative to control
condition was assessed for experimental treatments using 2 -∆∆Ct.

2.4
2.4.1

Fluorescent Staining
Surface Expression

Flow cytometry uses laser technology to assess physical and chemical properties of single
cells suspended in fluid. Fluorescent labelled antibodies are used to identify specific protein
or chemical markers. The fluorochromes are excited by lasers of specific wavelength and the
light emitted is then detected and assessed. Presence and intensity of light emission is used to
determine existence and relative abundance of a protein or chemical marker.
Surface expression of CRTh2 was assessed using flow cytometry. Cells (0.5x10 6cells) were
washed (PBS FACS) at 900rpm. Cells were pelleted and re-suspended (PBS FACS) at
5x106cells/ml. Cells were blocked for 45 minutes (room temperature) with 3mg/mL of Rat
IgG (Cederlane ON, Canada). Blocking was followed by cell staining with 75ng/mL of
CRTh2 Alexa647 antibody (BM16-rat IgG2a, Cederlane ON, Canada) or 75ng/mL of isotype
rat IgG2a Alexa647(Cederlane ON, Canada) for 30 minutes on ice. Cells were then washed
with 1mL of PBS FACS for 5 minutes at 900rpm and then re-suspended in 200uL of PBS
FACS and fixed with 200uL of 4% paraformaldehyde (final 2%). Data were presented as %
parent and mean fold intensity (MFI). MFI was calculated controlling for isotype (MFI=
[Mean Intensity Antibody – Mean intensity Isotype]/ Mean intensity Isotype).

21

2.4.2

Apoptosis

Experiments assessing apoptosis were set-up the day cells were re-seeded. Cells were treated
with 0.1µM-1µM dexamethasone treatment in the presence or absence of antagonist RU486
for 24 or 48 hours. Experiments testing PGD2 were pre-treated with DK-PGD2 30 minutes
prior to dexamethasone treatment.
Caspase 3/7(Cederlane ON, Canada) assay uses a fluorescently tagged peptide which enters
the cell and is cleaved by active caspase 3/7. The fluorescent dye is cleaved from the peptide
and can bind directly to DNA to emit fluorescence. The Sytox assay (Cederlane ON, Canada)
is a dye that can bind directly to DNA under conditions of cell death when cellular and
nuclear membrane integrity is compromised.
Cells (1mL) were collected and placed into 1.5mL Eppendorf tubes. 2 drops of caspase 3/7
and 1μL of Sytox was added to cells and mixed by inversion. Stains were incubated for 40
minutes (room temperature). Data were presented as percentage of cells positive for each
fluorescent stain.
Apoptosis and cell death following experimental treatments was assessed using Annexin V
and 7AAD, respectively. Cells were collected (0.5x106cells) and washed with PBS FACS at
900rpm for 10 minutes. Cells were re-suspended in 100μL of Annexin V binding buffer
(10mM Hepes, 140mM NaOH, 2.5mM CaCl2) at 5x106cells/mL. Double stain of 1μL of
Annexin V and 10μL of 7AAD was added to each condition. Cells were incubated for 15
minutes (room temperature). After incubation cells were diluted with 400μL of Annexin V
binding buffer. Data were presented as percentage of positive cells of parent population.

2.5

Statistical Analysis

All data were represented as mean + standard error. Unpaired and paired t tests or one-way
Anova were used to identify significance between conditions. Tukey’s Honest Significant
Difference (HSD) test was used to identify significant differences between conditions. P
values lower than 0.05 were considered significant differences.
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Chapter 3

3

Results

Allergic asthma is mostly dominated by Th2 cell mediated inflammation [26]. GCs are the
most common treatment for allergic asthma but the regulation of Th2 cells by GCs has not
been well characterized. In this study, we examined the effect of GCs on Th2 cells with a T
cell line (CCRF-CEM) that models a Th2 gene expression profile and validated these
findings with an in vitro differentiated primary Th2 cell line. Two major functions of the GR
are regulating mRNA transcripts either through transcription or stability and inducing
apoptosis [14]. The GR can regulate transcription of genes by binding positive GREs or
negative GREs to increase or decrease transcription, respectively [113]. GR mediated
apoptosis is initiated by activation of the caspase-3 enzyme [160]. Interestingly, CRTh2
activation by PGD2 has been shown to inhibit caspase-3 dependent apoptosis in response to
IL-2 starvation [98]. This indicates that GR mediated apoptosis may be inhibited in Th2
cells by CRTh2 activation. To have a complete understanding of the regulation of Th2 cells
by GCs, we must determine GC regulation of mRNA in Th2 cells activated via CD3/CD28.
T cell activation has been shown to inhibit both GR mediated transcription and apoptosis
through the up-regulation of AP-1 and NFκB [133, 134, 161]. GR self-regulation through
transcription of FKBP5 and GR is essential to sustaining GR function, whether this is
affected by T cell activation is unclear [115, 162]. The study aims to understand the
regulation of Th2 cells by GCs to enhance our knowledge of how GCs affect Th2 dominant
inflammation in the airways.
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3.1

CCRF-CEM Cells – A Th2-like cell line

We chose to initiate our study of GC using a cell line because of the relative ease of cell
culture and their accelerated growth (typically doubling daily). To choose a T cell line we
reviewed T cells commonly used in the literature. The CCRF-CEM cell line was chosen
based on its CRTh2 expression relative to other CD4+ T cells (Figure 3). CCRF-CEM cells
are an acute lymphoblastic leukemia CD4+ T cell line derived from a 4-year-old female
patient. Expression of CRTh2 was confirmed and other important Th2 genes (GATA3 and
IL-13) were assessed relative to Jurkat T cells, another cell line commonly used to study T
cell function [163]. We found that CCRF-CEM cells had higher mRNA transcript levels of
CRTh2 and GATA3 compared to Jurkat cells (Figure 3A). Activation using PMA and
ionomycin of CCRF-CEM cells demonstrated higher IL-13 mRNA levels relative to Jurkat
cells (Figure 3B). These results identified that CCRF-CEM cells are a better model to study
Th2 cell regulation by GCs compared to the Jurkat T cell line.
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Figure 3: Th2 gene expression of Th cell lines
Expression of Th2 genes in CCRF-CEM and Jurkat T cells were assessed using qRT-PCR.
The basal expression of CRTh2 and GATA3 (A) and expression of IL-13 in response to T
cell activation (B) was determined. Transcript levels are presented as 2-∆∆Ct and normalized
to housekeeping gene GAPDH and represent as mean fold difference + standard error (SE).
Statistical difference (p<0.05) detected by Student’s t-test. n=5.
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3.2

GC Regulation of CRTh2 Expression

CRTh2 is a marker of Th2 cells and its expression exemplifies a fully differentiated helper T
cell subset [86, 164]. CRTh2 expression by Th2 cells is important because CRTh2 mediates
chemotaxis, cytokine production and cell survival [95, 98, 99]. So far, GATA3 has been the
sole transcription factor shown to regulate CRTh2 transcription [165]. Sequence variants of
CRTh2 transcripts in the African American population have been associated with increased
stability and greater risk of asthma development [91]. These findings build on the data
identifying higher CRTh2 mRNA and CRTh2+ cells in the lungs of severe asthmatics that
take the highest dose of GCs [3, 4]. A positive correlation was also seen between the daily
dose of GCs and percentage of Th2 cells in circulation [3]. One of the main functions of the
GR is regulation of transcription by binding GREs [113]. Interestingly, preliminary data in
our lab generated using the Encyclopedia of DNA Elements (ENCODE) show that DNASE 1
hypersensitive sites on the CRTh2 promotor contain putative GRE (Naghdi, unpublished).
This provided further incentive to determine whether GCs regulate transcription of CRTh2.

3.2.1

Dexamethasone Regulates CRTh2 mRNA in CCRF-CEM cells

Dexamethasone is among the most potent oral GCs available clinically and has a half-life of
36-54 hours [166, 167]. Compared to prednisone which is a common oral GC prescribed for
asthma treatment, dexamethasone is 5 times more potent and has double the half-life [167].
Thus, we thought dexamethasone would be the best GC to use to help us understand the
potential of the GR signaling pathway to regulate transcription. The CRTh2 locus has been
shown to contain putative GR binding sites. Determining whether the GR regulates CRTh2
transcription will help us to understand how GCs regulate Th2 cell function. The level of
CRTh2 mRNA transcripts in response to kinetic and titration experiments of dexamethasone
were performed using CCRF-CEM cells (Figure 4). No changes in CRTh2 mRNA transcript
levels were seen at 2 hours (Figure 4A), there were reduced levels at 6h (Figure 4B) and no
change at 12 hours (4C) of dexamethasone treatment. CRTh2 mRNA levels were higher in
response to GC treatment of 0.01μM-1μM after 24 hours (Figure 4D). Interestingly the
increase in CRTh2 transcript levels plateaued at 0.01μM dexamethasone. This increase in
CRTh2 mRNA transcripts was inhibited by RU486 (Figure 4E), an antagonist that blocks
GRE binding, indicating that the GR directly regulates transcription of CRTh2.
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Figure 4: CRTh2 mRNA transcript levels in response to dexamethasone treatment
CRTh2 mRNA transcript levels were assessed by qRT-PCR after 2 hours (A), 6 hours(B), 12
hours (C), and 24 hours (D) of dexamethasone treatment in CCRF-CEM cells. The antagonist
RU486 was added with dexamethasone to inhibit GR activity (E). Transcript levels are
presented as 2-∆∆Ct and normalized to housekeeping gene GAPDH and represent mean fold
difference relative to vehicle + SE. Statistical difference (p<0.05) detected by one way
ANOVA. V=vehicle (ETOH 0.004%); n =3-19.
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3.2.2

Hydrocortisone Regulation of CRTh2 mRNA in CCRF-CEM cells

Hydrocortisone is found naturally in the body and is produced in response to stress.
Compared to dexamethasone, hydrocortisone is a weaker GR agonist [166]. We wanted to
determine whether GR regulation of CRTh2 mRNA was dependent on GC potency. The
level of CRTh2 mRNA transcripts appeared to increase, though this change was not
statistically significant, due to the lack of statistical power.
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Figure 5: CRTh2 mRNA transcript levels in response to hydrocortisone treatment
CRTh2 mRNA transcript levels were assessed by qRT-PCR after 24 hours of hydrocortisone
treatment in CCRF-CEM cells. Transcript levels are presented as 2 -∆∆CT, normalized to
housekeeping gene GAPDH and represented as mean fold difference relative to vehicle + SE.
HC= hydrocortisone; V=vehicle (ETOH 0.004%); n =3.

3.2.3

Dexamethasone Regulates FKBP5 mRNA levels

FKBP5 which is a chaperone protein that keeps the GR in the cytoplasm and in an active
state within the GR heterocomplex [110]. To sustain GR function, there is feed-forward
regulation by the GR that increases FKBP5 transcription [115]. FKBP5 was used as a
positive control for GR-induced effect on transcripts to assess the level of GR function at
different concentrations. We assessed FKBP5 mRNA transcript levels to determine GC
regulation in CCRF-CEM cells (Figure 6). A dose dependent increase in FKBP5 mRNA
transcript levels was seen, with the first increase at 6 hours (Figure 6A) and continual
increase after 24 hours (Figure 6B). Incorporation of RU486 with dexamethasone for 24
hours inhibited the increase in FKBP5 mRNA transcript levels (Figure 6C). FKBP5 mRNA
transcript levels showed a dose dependent induction in response to dexamethasone treatment
in CCRF-CEM cells.
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Figure 6: FKBP5 mRNA transcript levels in response to dexamethasone treatment
FKBP5 mRNA transcript levels were assessed over time with qRT-PCR after 6 hours (A)
and 24 hours (B) of dexamethasone treatment in CCRF-CEM cells. The antagonist RU486
was added with dexamethasone to inhibit GR activity (C). FKBP5 mRNA transcript levels
were assessed using 2-∆∆Ct and normalized to housekeeping gene GAPDH. Data represented
as mean fold difference relative to vehicle + SE. Statistical difference (p<0.05) detected by
one-way ANOVA. V=vehicle (ETOH 0.004%); n =3-6.
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3.2.4

Dexamethasone Regulation of CRTh2 Surface Expression in CCRFCEM cells

CRTh2 is a seven-transmembrane spanning G-protein coupled receptor, thus its expression
on the membrane requires the work of multiple folding and transport proteins [168]. Previous
research using transfected T cells demonstrated that CRTh2 mRNA levels are reflected by
total protein levels in the cell [80]. We treated CCRF-CEM cells with dexamethasone and
assessed whether the change in CRTh2 mRNA levels we detected (Figure 4D) are reflected
by the CRTh2 surface expression (Figure 7). After 24 hours of dexamethasone treatment
there were no significant changes in the percentage of cells positive for CRTh2 (Figure 7A)
or the abundance of receptors per cell, represented by mean fold intensity (Figure 7B). These
results indicate that the changes in CRTh2 mRNA did not translate to surface expression.
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Figure 7: CRTh2 surface expression in response to dexamethasone treatment
Expression of CRTh2 on the cell surface was assessed using flow cytometry. CRTh2 levels
were determined in response to dexamethasone treatment in CCRF-CEM cells for 24 hours.
The data were represented as percentage of cells expressing CRTh2 (A) and mean fold
intensity representing the abundance of CRTh2 receptors per cell (B). Data represented as
means + SE. V=vehicle (ETOH 0.004%); n = 7.
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3.2.5

Dexamethasone Regulates CRTh2 mRNA in Primary Th2 cells

Due to the lack of agreement between CRTh2 mRNA and protein in CCRF-CEM cells, we
next turned to in vitro differentiated Th2 cells as a more physiologically relevant cell type to
assess the GC effect on CRTh2 expression. Transcript levels of CRTh2 and FKBP5 in
response to dexamethasone treatment for 24 hours were assessed (Figure 8). CRTh2 mRNA
levels (Figure 8A) were higher in response to dexamethasone treatment at concentrations of
0.01μM and above but did not differ between doses. The fold induction in primary Th2 cells
was higher (~4 fold) then what was previously seen with dexamethasone treatment of CCRFCEM cells (~2 fold; Figure 4D). FKBP5 mRNA transcript levels also increased in response
to dexamethasone in a dose dependent manner. The results replicate the mRNA changes seen
in CCRF-CEM cells, but show that in primary Th2 cells GC upregulates CRTh2 mRNA to an
even greater extent.
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Figure 8: mRNA transcript levels in primary Th2 cells
CRTh2 (A; n=5) and FKBP5 (B; n=3) mRNA transcript levels were assessed using qRTPCR in response to dexamethasone. Transcript levels are presented as 2 -∆∆Ct and normalized
to housekeeping gene GAPDH and represent mean fold difference relative to vehicle + SE.
Statistical difference (p<0.05) detected by one-way ANOVA. V=vehicle (ETOH 0.004%).
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3.2.6

Dexamethasone Regulates CRTh2 Surface Expression in Primary Th2
cells

CRTh2 mRNA transcripts were increased in both CCRF-CEM and primary Th2 cells in
response to 24 hours of dexamethasone treatment. Although previous studies have indicated
that CRTh2 mRNA changes are reflected at the protein level, this was not seen with CRTh2
surface expression in CCRF-CEM cells (Figure 7) [80]. To determine whether changes in
CRTh2 mRNA transcript levels are reflected with CRTh2 surface expression we treated
primary Th2 cells with dexamethasone (Figure 9). When assessing all doses of
dexamethasone together we saw that with a one-way ANOVA there were no significant
changes in percentage of cells positive for CRTh2 (Figure 9A) or the abundance of receptors
per cell, represented by mean fold intensity (Figure 9C). On the other hand, when we looked
at the vehicle in comparison to the lowest concentration of dexamethasone needed to see
mRNA changes (Figure 8A) we saw a significant difference using a Paired t-test in both the
percentage of cells positive for CRTh2 (Figure 9B) and abundance of CRTh2 receptors per
cell (Figure 9D). This indicates that at low concentrations of dexamethasone CRTh2 surface
expression is also increased.

3.2.7

Dexamethasone Regulates IL-13 Expression in Primary Th2 cells

The ability of GCs to regulate CRTh2 expression may help promote Th2 inflammation,
which is contrary to previous in vivo studies showing that GCs reduce type 2 cytokines [127,
169]. Even in the case of Th2 high asthma the reduction of IL-13 in response to GCs is an
indicator of steroid sensitivity [26]. As such, we wanted to determine whether GCs reduce
IL-13 mRNA levels despite increasing CRTh2 mRNA. To test whether GCs can reduce IL13 mRNA levels we treated primary Th2 cells with dexamethasone for 24 hours (Figure 10)
and found that there was a dose dependent reduction in IL-13 mRNA levels at the lowest
concentration of dexamethasone (0.01µM). These data show GCs can reduce IL-13
expression but at the same time increase CRTh2 expression.
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Figure 9: CRTh2 surface expression in response to dexamethasone treatment
Expression of CRTh2 on the surface of the cell was assessed using flow cytometry. CRTh2
levels were determined in response to dexamethasone treatment for 24 hours. The data were
represented as percentage of cells expressing CRTh2 (A, C) and mean fold intensity
representing the abundance of CRTh2 receptors per cell (B, D). Data represented as means +
SE V=vehicle (ETOH 0.004%); Statistical difference (p<0.05) detected by using paired Ttest. n = 7.
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Figure 10: IL-13 mRNA levels in primary Th2 cells in response to dexamethasone
IL-13 mRNA levels were assessed using qRT-PCR in primary Th2 cells treated with
dexamethasone for 24 hours. Transcript levels are presented as 2 -∆∆CT, normalized to
housekeeping gene GAPDH and represented as mean fold difference relative to vehicle + SE.
V=vehicle (ETOH 0.004%); n =5.

3.3

Glucocorticosteroid Induced Apoptosis in Th2 cells

In addition to suppressing Th2 cytokines, another function of GCs is the ability to induce
apoptosis in inflammatory cells in a dose and time dependent manner [144]. GC-induced
apoptosis in naïve and memory T cells has been well documented but no studies have been
completed specifically in Th2 cells [141-143]. PGD2 binding CRTh2 activates the PI3K
pathway which has been shown to inhibit apoptosis induced by IL-2 starvation in Th2 cells
by inhibiting BAD interference of anti-apoptotic BCL proteins [98]. Downregulation of BCL
proteins induces GC-induced apoptosis, thus there is competition between pathways
activated by GCs and PGD2 [98, 141, 151]. Severe asthmatics who take the highest dose of
GCs have been shown to have a higher level of PGD2 relative to other asthmatics [4]. If
PGD2 can inhibit GC-induced apoptosis, Th2 cells may be sustained in severe asthmatics
even though they take high dose GCs. As such, we wanted to test whether CRTh2 signaling
could inhibit GC-induced apoptosis and render Th2 cells GC resistant.
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3.3.1

Dexamethasone Regulates Apoptosis in CCRF-CEM cells

The effect of GCs is dependent on dose and exposure time and most importantly dependent
on cell type as demonstrated by opposing apoptotic effects seen in eosinophils versus
neutrophils [144, 145]. To determine whether PGD2 can inhibit GC-induced apoptosis it was
important to first establish the dose and time of exposure needed to induce apoptosis. CCRFCEM cells were treated with dexamethasone for 24 and 48 hours to assess the ability of GCs
to induce apoptosis. To test whether cells were undergoing apoptosis and cell death we used
Caspase 3/7 and Sytox fluorescent stains, respectively. After 24 hours of exposure to various
concentrations of dexamethasone treatment there were no changes in apoptosis (Figure 11A)
or cell death (Figure 11B). After 48 hours of 1μM dexamethasone there was a significant
increase in apoptosis (Figure 11C) and cell death (Figure 11D). Induction of apoptosis was
related directly to the ability of GCs to influence transcription as the effect was inhibited by
RU486.
GC-induced apoptosis results from the release of cytochrome C and downstream activation
of caspase-3 to induce cell death [170]. We wanted to use a more sensitive assay to ensure
we did not miss any apoptotic effects after 24 hours of dexamethasone treatment. We used
the stain Annexin V which binds phosphatidylserines to detect early apoptotic changes at the
cell surface of viable cells [106]. To do this CCRF-CEM cells were treated with various
concentrations of dexamethasone (24 and 48 hours) and stained for Annexin V and 7AAD
(Figure 13). Similar to Figure 11 there was no significant apoptosis or cell death after 24
hours of dexamethasone treatment (Figure 12A,12B), but again we see that after 48 hours of
1µM dexamethasone treatment there is an increase in both apoptosis and cell death (Figure
12C, D). Induction of apoptosis by GCs was inhibited by antagonist RU486.

34

A

B

24 hours

24 hours
5

4

% of Sytox Positive Cells

% of Caspase 3 Positive Cells

5

3

2

1

0

V

C

3

2

1

0

1µM dex +
1µM RU486

0.1 M dex 1 M dex

4

V

D
48 hours

48 hours

25

25

*

*
20

*

% of Sytox Positive Cells

% of Caspase 3 Positive Cells

1µM dex +
1µM RU486

0.1 M dex 1 M dex

15

10

5

0

V

0.1 M dex 1 M dex

1µM dex +
1µM RU486

*

20

15

10

5

0

V

0.1 M dex 1 M dex

1µM dex +
1µM RU486

Figure 11: Dexamethasone induced apoptosis in CCRF-CEM cells
CCRF-CEM cells were treated with dexamethasone for 24 and 48 hours with and without
antagonist RU486 to determine apoptosis and cell death using fluorescent stains. After 24
hours the percentage of caspase 3/7 positive cells (A) and Sytox positive cells (B) indicated
apoptosis and cell death, respectively. After 48 hours the percentage of caspase 3/7 positive
cells (C) and Sytox positive cells (D) indicated apoptosis and cell death, respectively. Data
represented as means + SE. Dex = dexamethasone; V=vehicle (ETOH 0.004%); Statistical
difference (p<0.05) detected by using one way ANOVA. n = 4.
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Figure 12: Dexamethasone induced apoptosis
CCRF-CEM cells were treated with dexamethasone for 24 and 48 hours with and without
antagonist RU486 to determine apoptosis and cell death using flow cytometry. Percentage of
Annexin V positive cells identified dexamethasone induced apoptosis for 24 hours (A) and
48 hours (C). Cell death was assessed by cells positive for 7AAD after 24 hours (B) and 48
hours (D). Data represented as mean fold difference relative to vehicle + SD; dex =
dexamethasone; V=vehicle (ETOH 0.004%); Statistical difference (p<0.05) detected by
using one way ANOVA. n = 4.
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3.3.2

PGD2 Does Not Regulate Dexamethasone Induced Apoptosis in
CCRF-CEM cells

GR induction of apoptosis and CRTh2 inhibition of apoptosis are both are regulated by
similar pathways but in the opposite manner [98, 141]. PGD 2 binding to CRTh2 activates
AKT signaling which inhibits caspase-3 mediated apoptosis, while GCs induce caspase-3
mediated apoptosis [98, 141]. CRTh2 has been shown to inhibit apoptosis but only in the
context of IL-2 starvation [98]. To determine whether CRTh2 and GC activated pathways
compete to maintain Th2 cell survival, we pre-treated CCRF-CEM cells with CRTh2 specific
agonist, the PGD2 metabolite DK-PGD2 before treating with dexamethasone for 48 hours
(Figure 13). DK-PGD2 did not reduce the percentage of Annexin V+ cells in response to GC
treatment. These results may be due to a limitation of the CCRF-CEM cells ability to regulate
CRTh2.
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Figure 13: DK-PGD2 does not inhibit GC-induced apoptosis in CCRF-CEM cells
CCRF-CEM cells were pre-treated with DK-PGD2 and then dexamethasone for 48 hours.
Data represented as means + SE. Early apoptosis was determined by Annexin V positive
cells. V=vehicle (ETOH 0.004%); Statistical difference (p<0.05) detected by using one-way
ANOVA. n=5.
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3.3.3

IL-2 Inhibits Glucocorticosteroid Induced Apoptosis in Primary Th2
cells

IL-2 is a survival factor that is required to maintain T cells in culture [154]. IL-2 signals
through AKT to inhibit apoptosis induced by GCs [171]. We have determined that 1µM
dexamethasone was required to induce apoptosis in CCRF-CEM cells, but these cells were
not cultured with IL-2. We needed to determine the concentration of IL-2 needed to maintain
Th2 cells but still leave them susceptible to apoptosis. We treated cells with decreasing
concentrations of IL-2 with and without dexamethasone and assessed percentage of Annexin
V+ cells (Figure 14). Cells treated with decreasing concentrations of IL-2 (5-0ng/mL) show a
dose response to 1μM dexamethasone induced apoptosis. 0ng/mL of IL-2 had significant
apoptosis in the absence of dexamethasone. Thus, these results indicate that 1.25ng/mL of
IL-2 sustained Th2 cells while still permitting GC sensitivity.
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Figure 14: IL-2 inhibits dexamethasone induced apoptosis
The ability of dexamethasone to induce apoptosis with varying amounts of IL-2 was
identified by Annexin V positive cells using flow cytometry. Primary Th2 cells were treated
with dexamethasone and decreasing amounts of IL-2 for 48 hours to assess cell apoptosis.
Data represented as means + SE. V= vehicle (0.04% ETOH). Statistical difference (p<0.05)
detected by using one way ANOVA and Tukey’s HSD test. n=3.
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3.3.4

PGD2 Does Not Regulate Dexamethasone Induced Apoptosis in
Primary Th2 cells

CCRF-CEM cells that were pre-treated with DK-PGD2 did not show any changes in
dexamethasone induced apoptosis. Primary Th2 cells were used to replicate the previous
experiments assessing PGD2 inhibition of apoptosis. In these experiments, Th2 cells were
cultured in 1.25ng/mL of IL-2 which we determined was sufficient to maintain Th2 cells and
render cells susceptible to GCs (Figure 14). Primary Th2 cells were pre-treated with DKPGD2 followed by dexamethasone treatment and assessed for apoptosis using Annexin V
staining. However, there were no differences in the percentage of Annexin V + cells in
response to dexamethasone treatment after DK-PGD2 pretreatment (Figure 15).
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Figure 15: DK-PGD2 does not inhibit dexamethasone induced apoptosis
To assess the ability of CRTh2 signaling to inhibit apoptosis, primary Th2 cells cultured with
1.25ng/mL of IL-2 were pre-treated with DK-PGD2 and then treated with dexamethasone.
Early apoptosis was determined by Annexin V positive cells using flow cytometry. Data
represented as means + SE; V=vehicle (ETOH 0.004%); n = 3.
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3.4

Glucocorticosteroid Regulation of Transcription in Activated T
cells

A large component of chronic inflammation in asthma is the constant activation of Th2 cells
via dendritic cells [44]. CD3 and CD28 co-stimulation of Th2 cells up-regulates transcription
factors NFAT, AP-1 and NFκB to induce cytokine production and regulate inflammation [53,
158, 172]. Production of type 2 cytokines can be inhibited by GCs as indicated in literature
and demonstrated with our own work (Figure 10) [127]. Interestingly, AP-1 and NFκB have
both been shown to inhibit GR induced transcription [134, 161]. The GR has also been
shown to reciprocally inhibit AP-1 and NFκB, as GC treatment of T cells increased the
threshold for T cell activation [173]. Thus, GR and the T cell activation pathways compete
and interfere with each other. Severe asthmatics have the highest percentage of Th2 cells in
circulation, thus if T cell activation inhibits GC regulation of Th2 cells, chronic exposure to
allergens may render Th2 cells GC insensitive [3]. To fully understand how GCs regulate
Th2 cells we wanted to look at GR function in the context of activated Th2 cells.

3.4.1

Dexamethasone Regulates IL-13 mRNA in CCRF-CEM cells

T cell activation induces expression of type 2 cytokines IL-4, IL-5, and IL-13 [55, 135].
Interestingly, activated T cells have been deemed GC resistant but cytokines can be inhibited
by GCs [159, 174]. Our previous results indicated that GCs could reduce IL-13 mRNA levels
in primary Th2 cells, even at low dose (0.01µM; Figure 11). If T cell activation inhibits GC
function, then the extent of IL-13 regulation by GCs may be repressed. To determine whether
GCs can inhibit cytokine expression with T cell activation, CCRF-CEM cells were activated
with PMA and ionomycin (Figure 16). IL-13 mRNA transcript levels were reduced in
response to dexamethasone treatment though the reduction was only about 30% compared to
(80%) reduction seen in primary Th2 cells. These results suggest that the GR still retains its
ability to inhibit IL-13 production after T cell activation.
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Figure 16: Dexamethasone reduces IL-13 mRNA transcript levels in activated T cells
The dexamethasone response of activated CCRF-CEM cells was assessed using qRT-PCR
after 24 hours. IL-13 mRNA transcript levels were assessed using 2- ∆∆Ct and normalized to
housekeeping gene GAPDH. Data represented as mean fold difference relative to vehicle +
SE. P= PMA; I= ionomycin; V=0.004% ETOH); Statistical difference (p<0.05) detected by
using one-way ANOVA. n=5.

3.4.2

T cell Activation Interferes with Dexamethasone Regulation of GR
Signaling Genes in CCRF-CEM cells

Upon GC binding, the GR increases transcription of FKBP5 and GR, to sustain GR function.
Although T cell activation has been shown to inhibit GR mediated transcription, it has not
been shown whether there is a similar effect on the feed forward loop of GCs increasing
expression of genes within its own signaling pathway. To test this CCRF-CEM cells were
activated with PMA and ionomycin to mimic CD3 and CD28 mediated T cell activation and
with or without dexamethasone. The level of FKBP5 and GR mRNA transcripts in response
to dexamethasone treatment in resting and activated cells was assessed (Figure 17). As
expected both FKBP5 and GR mRNA transcript levels were increased in response to
dexamethasone treatment. But, with the addition of PMA and ionomycin the dexamethasone
effect on the level of FKBP5 and GR mRNA transcripts were reduced. This builds on
previous studies, as these data demonstrate that activation of T cells reduces GR mRNA
transcripts and thereby GR activity, to render Th2 cells less sensitive to GCs.
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Figure 17: Dexamethasone regulation is inhibited by T cell activation
The dexamethasone response in activated CCRF-CEM cells was assessed using qRT-PCR
after 24 hours. FKBP5 (A) and GR (B) mRNA transcript levels were assessed using 2- ∆∆Ct
and normalized to housekeeping gene GAPDH. Data represented as mean fold difference
relative to vehicle + SE. V= 0.004% ETOH; P= PMA; I = Ionomycin; Statistical difference
(p<0.05) detected by using one way ANOVA. n=5.
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3.4.3

Dexamethasone Does Not Regulate CRTh2 Expression in Activated T
cells

One of the novel findings of this study was the identification that GCs regulate CRTh2
mRNA levels (Figure 4). This GC regulation of CRTh2 may have vast implications in
relevance to Th2 cell function [95, 98, 99]. Interestingly, CRTh2 expression has been shown
to be downregulated by T cell activation [80]. We have seen that T cell activation reduces
GR activity as demonstrated by lower levels of FKBP5 and GR mRNA transcripts (Figure
18). Despite reduced GR signaling genes these conditions did not completely inhibit the
ability of GCs to reduce IL-13 mRNA levels (Figure 16). To determine whether GCs could
increase CRTh2 expression in the presence of T cell activation we treated CCRF-CEM cells
with dexamethasone and PMA and Ionomycin (Figure 18). As previously shown, CRTh2
mRNA levels were increased with dexamethasone treatment but with the addition of PMA
and ionomycin there was significant drop that was reversed by dexamethasone.

CRTh2 mRNA Transcript Level
mRNA Normalized to GAPDH

3.0

*
*

2.5
2.0
1.5
1.0
0.5
0.0

V

1µM dex

P+ I

1µM dex+ P+ I

Figure 18: Dexamethasone induction of CRTh2 is inhibited by T cell activation
The dexamethasone response in activated CCRF-CEM cells was assessed using qRT-PCR
after 24 hours. CRTh2 mRNA transcript levels were assessed using 2- ∆∆Ct and normalized to
housekeeping gene GAPDH. Data represented as mean fold difference relative to vehicle +
SE. V= 0.004% ETOH; P= PMA; I = Ionomycin; Statistical difference (p<0.05) detected by
using one way ANOVA. n=5.
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Chapter 4 : Discussion

4

Summary

Severe asthmatic patients have a higher percentage of CRTh2+ cells in the airways and Th2
cells in circulation, relative to mild/moderate asthmatics [3, 4]. Interestingly, Palikhe et al
identified a positive correlation between the percentage of Th2 cells in the blood of
asthmatics and the daily dose of inhaled GCs taken [3]. Naturally, this finding provided
incentive to study the effects of GC on Th2 cells.
An immortalized CD4+ T cell line (CCRF-CEM) and in vitro differentiated primary Th2 cells
were examined with varying concentrations and times of exposure to dexamethasone and its
antagonist RU486. We found that the dexamethasone effect on gene expression and
apoptosis was concentration dependent. Low concentration of GCs (0.01µM) increased the
level of CRTh2 mRNA and surface expression after 24 hours, while reducing the expression
of the type 2 cytokine IL-13. Th2 cells exposed to high concentration GC (1µM) for 48 hours
triggered apoptosis, but this was not inhibited by PGD2. We also examined GC regulation of
mRNA transcripts in response to T cell activation, which has been shown to reduce GC
mediated transcription and apoptosis [134, 159]. We found that IL-13 expression was
reduced (30%) with dexamethasone in activated CCRF-CEM cells and to a greater extent in
primary cells (80%). These data suggest that activation may dampen Th2 cell response to
GCs. Overall the effect of GCs on Th2 cells proves to be complex and to depend on dose,
time of exposure and state of activation. This study provides further insight into the potential
mechanisms of GC regulation of Th2 cells. Insufficient dose of inhaled GC in vivo may result
in higher expression of CRTh2, leading not only to ineffective anti-inflammatory action but
enhancing the pro-inflammatory potential of Th2 cells.

4.1

Glucocorticosteroids Regulate Th2 cell expression of CRTh2

GCs regulate transcription by binding GREs [150]. Whether GCs mediate up-regulation or
down-regulation of gene transcription is dependent on dose, time of exposure and cell type
[113, 166]. Despite its use as an anti-inflammatory drug GCs have been shown to increase
transcription of pro-inflammatory genes [119, 175].
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We examined the effect of the GC dexamethasone on CCRF-CEM cells at various time
points (24-48 hours) and concentration (0.01-1μM). We found that a concentration of
dexamethasone of 0.01μM and higher was associated with more CRTh2 mRNA transcripts
after 24 hours (2-fold). This upregulation of CRTh2 transcripts was not observed with
hydrocortisone, which is a less potent GR agonist then dexamethasone [166]. Further
replicates and/or higher concentrations of hydrocortisone may have been necessary to see
significant changes in CRTh2 mRNA. The level of CRTh2 mRNA transcript plateaued with
the lowest dose of dexamethasone (0.01µM), which was the minimum concentration needed
to induce FKBP5, a gene known to be regulated at the transcriptional level by GCs [114].
Interestingly, after 24 hours FKBP5 showed a dose response with a maximum increase (8fold). This suggests that the GR regulation of CRTh2 and FKBP5 differ. The plateau of
CRTh2 mRNA levels at low concentration is similar to that seen with transcriptional
regulation of Period circadian protein homolog (PER) [113]. The GR antagonist RU486
inhibited this change in CRTh2 mRNA, which indicates GC mediated transcriptional
regulation. Our lab has identified potential GREs on the CRTh2 locus using ENCODE data,
in DNase hypersensitive sites that were uniquely present in the Th2 cells (Figure 4) [115].
Thus, direct GR regulation of CRTh2 is possible. This low concentration GC response of
CRTh2 mRNA may indicate that another transcription factor interacts with the GR and is the
transcription limiting protein. For example, the GR has been shown to interact with ERα and
AP-1 [176]. The potential for GR and ERα interaction to regulate CRTh2 could be interesting
and provide insight into the disproportionate representation of severe asthma among females
[2].
Using flow cytometry, surface expression of CRTh2 was assessed and typically showed ~2040% positivity. Interestingly, in CCRF-CEM cells surface expression in response to
dexamethasone treatment did not reliably reflect the mRNA changes. This discrepancy may
be associated with features particular to CCRF-CEM cells, an immortalized cancer T cell
line. This was surprising, since the abundance of CRTh2 mRNA in these cells was quite high
(Ct ~26). This could be due to the fact that this line grows particularly fast, doubling every 24
hours, and may therefore be constantly shuttling CRTh2 to and from the surface.
Alternatively, it is possible the CCRF-CEM cells may not have a robust representation of the
machinery needed for membrane transport of CRTh2. For example, mast cells have been
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shown to have intracellular expression of CRTh2 but little on the cell surface, presumably
due to the lack of machinery [83]. CCRF-CEM cells may be like mast cells and lack
sufficient amount of the proteins needed to transport CRTh2. Further work such as
performing western blot analysis for total abundance of CRTh2 protein and/or intracellular
CRTh2 staining should be done and could help us understand this discrepancy,
To address the limitation in CCRF-CEM cells we chose to examine dexamethasone effects
using more physiologically relevant in vitro differentiated Th2 cells. To determine whether
the CRTh2 mRNA levels are reflected at the surface, we repeated these dexamethasone
treatments using primary Th2 cells. I found that after 24 hours, 0.01-1μM dexamethasone
treatment increased CRTh2 mRNA transcript levels in primary Th2 cells, to greater extent
(4-fold) then CCRF-CEM cells (2-fold). The percentage of cells positive for CRTh2 and
abundance of CRTh2 per cell was increased in response to 0.01μM treatment but not at
higher concentrations. Interestingly, this was the lowest concentration of dexamethasone and
yet was the only dose that had an effect on CRTh2 surface expression. Determining total
CRTh2 protein with techniques such as a Western blot may indicate that total CRTh2
changes reflect mRNA transcript changes. Since proteins involved in CRTh2 membrane
transport have not been identified the effect GCs have on CRTh2 transport is unclear, but it is
plausible that at high doses GCs may affect expression or activity of these proteins.
The ability of GCs to increase CRTh2 transcription is novel and provides new insight into
how GCs may regulate Th2 cells. However, these results are contradictory to the antiinflammatory effects of GCs, particularly the ability of GCs to inhibit type 2 cytokine
production [121, 123]. Our finding of increased CRTh2, but inhibition of IL-13, could mean
that at low concentration GC can mediate suppression of Th2 inflammation, but maintenance
of Th2 cells. Specifically, with patients that have high level of Th2 cells in their airways or
blood the low dose GC treatment could worsen the disease over time. If so, this could have
significant clinical implications since the GC available in vivo is dependent on multiple
factors such as amount prescribed, compliance as well as the individual’s GC metabolism.
Therefore, getting the dose within the therapeutic range for suppression of inflammation is
important, as lower amounts could contribute to GC-mediated persistence of Th2 cells.
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4.2

GCs Induce Apoptosis in Th2 cells

One of the major functions of GCs is the ability to induce apoptosis of T cells [177]. GCs
mediate apoptosis by reducing the anti-apoptotic proteins BCL-2 and BCL-xL and activating
caspases [141]. The ability of GCs to induce apoptosis is dependent on dose and exposure
time, with different cell types varying in sensitivity [144]. To assess the ability of Th2 cells
to regulate GC-induced apoptosis we needed to determine the dose and exposure time of GC
needed to induce apoptosis.
To determine this, we treated CCRF-CEM cells with dexamethasone and identified that 48
hours (but not 24 hours) of high dose dexamethasone (1μM) treatment induced apoptosis. It
is interesting to note that 1µM concentration also resulted in elevated CRTh2 mRNA
transcript levels, suggesting that induction of apoptosis likely outweighs any potential proinflammatory effect. However, dexamethasone concentrations up to 1μM exposed for 48
hours were not able to induce apoptosis in primary Th2 cells. The GC resistance exhibited by
primary Th2 cells were a result of the 5ng/mL of IL-2 used to culture the cells. Similar to
PGD2-CRTh2 activation, IL-2 activates the AKT pathway which inhibits caspase-3 mediated
apoptosis [171]. Previous studies by Xue et al. indicated that in the absence of IL-2, Th2
cells undergo apoptosis [98]. Therefore, in order to assess apoptosis in primary Th2 cells we
had to first determine the amount of IL-2 that will sustain the cells but will permit a GC
response. We found 1.25ng of IL-2 permitted Th2 cells to become responsive to GC-induced
apoptosis. At higher doses of GCs the apoptotic ability of GR may outweigh the level of IL-2
present, again going back to the importance of sufficient amounts of GCs. This is relevant
clinically because cells from severe asthmatics have been shown to produce high levels of
IL-2 and have more Th2 cells relative to mild/moderate asthmatics [3, 30]. Thus, if severe
asthmatic patients have more IL-2 this may reduce the Th2 cells response to GC.

4.3

PGD2 Does Not Rescue Th2 cells From Glucocorticosteroid
Induced Apoptosis

PGD2 binding to CRTh2 has been shown to inhibit apoptosis induced by IL-2 starvation [98].
CRTh2 activates PI3K signaling pathway which leads to the inhibition of BAD and prevents
BAD from interfering with anti-apoptotic BCL proteins (Figure 21) [98], while GCs can
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downregulate BCL proteins to induce apoptosis. Therefore, these two pathways overlap and
compete [142]. This is significant because PGD2 levels correlate with asthma severity,
indicating patients with the highest level of Th2 cells have the highest levels of PGD 2 [4]. If
PGD2 can inhibit GC-induced apoptosis, then this may be a reason for Th2 cells to be
sustained in circulation.
To test this, we pre-treated CCRF-CEM cells with DK-PGD2 for 30 minutes in the presence
and absence of 1μM dexamethasone. However, we found that DK-PGD 2 did not inhibit GCinduced apoptosis. We considered whether this was related to the CCRF-CEM cell line and
whether these cells were unable to respond to PGD2 stimulation. To test this we assessed the
ability of DK-PGD2 to drive type 2 cytokine expression [99]. Preliminary data from the lab
shows that CCRF-CEM cells did not have detectable levels of IL-13 mRNA transcripts
following PGD2 treatment (3, 6, 8 12, and 24 hours). CRTh2 is a GPCR, thus when activated
results in calcium mobilization [95]. However, preliminary data of calcium flux, showed the
absence of calcium mobilization following stimulation of CCRF-CEM cells with DK-PGD 2.
We also used the more potent agonist 15-R-Methyl PGD2 and found similar results. The
reason for our inability to activate CRTh2 signaling is difficult to pinpoint and again may be
related to using a leukemia cell line.
To determine whether the lack of response from DK-PGD2 was a limitation of the cell line,
we examined the effect of DK-PGD2 with Th2 cells cultured with 0 or 1.25 ng/mL of IL-2.
We found that the percentage of Annexin V+ cells was not reduced with DK-PGD2 pretreatment. However, there are many factors to consider with these experiments and we are
still not confident in this negative result. Reducing the concentration of IL-2 renders Th2
cells more responsive to GC-induced apoptosis, which may alter the optimal time to detect
apoptotic effects. Indeed, after only 24 hours we observed a high proportion of apoptotic
cells (40%) with 0ng of IL-2 (data not shown). Therefore, future experiments could reassess
the ability of PGD2 to inhibit apoptosis at earlier time points. Secondly, the fact that IL-2 and
PGD2 are both survival factors activating the PI3K/AKT pathway suggests that perhaps the
lack of PGD2 effect may be related to growth factors in the media, though experiments
completed with 0, 0.5 and 5% serum, showed no difference in the ability of DK-PGD 2 to
reduce apoptosis (preliminary data). Finally, it is important to recognize that Th2 cells
express HPGDS, the enzyme that produces PGD2 [4]. For this reason, we considered the
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possibility that endogenous PGD2 production was reducing the ability of Th2 cells to respond
to exogenous PGD2. To test this, we performed a set of experiments where we cultured the
cells in cyclooxygenase inhibitor, to inhibit PGD2 production (preliminary data). However,
this too failed to alter the ability of PGD2 to inhibit GC-induced apoptosis or induce IL-13
expression (data not shown). Another possibility is that these cells have upregulated proteins
that inhibit CRTh2 signaling. For instance, β-arrestin has been shown to bind to the cterminal end of CRTh2 and inhibit its activity [178]. Ultimately, western blot coimmunoprecipitation experiments are needed to assess CRTh2-β-arrestin interaction to
confirm this possibility. If they do interact then we could utilize siRNA to knockdown βarrestin expression to confirm this recovers PGD2-CRTh2 signaling and then re-assess the
effect PGD2 on GC-induced apoptosis.

Figure 19: Regulation of Apoptosis in Th2 cells
Th2 cell regulation of apoptosis involves different factors but all converge to anti-apoptotic
BCL family proteins. Apoptosis induced by IL-2 starvation allows BAD to inhibit BCL
proteins allowing for cytochrome C release from the mitochondria (1). GCs upregulates
expression of GILZ which downregulates BCL proteins to induce apoptosis (2). Apoptosis
can be inhibited by activation of CRTh2 (3) and IL-2 (4) through PI3K signaling which
inhibits the BAD protein.
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4.4

T Cell Activation Inhibits Glucocorticosteroid Signaling

The effect of GCs on Th2 cells is important in both the resting and activation state. Th2 cells
in vivo are activated by dendritic cells to elicit an inflammatory response to an allergen [44].
CD3 and CD28 engagement activates pro-inflammatory transcription factors such as NFAT,
AP-1 and NFκB [158, 172]. Signaling pathways activated in T cells and pathways activated
by GCs overlap and thus may interfere with each other. For instance, GR and AP-1 have
been shown to demonstrate reciprocal inhibition [133].
Therefore, to determine the effect of GCs on activated T cells, CCRF-CEM cells were treated
with dexamethasone in the presence or absence of PMA and Ionomycin, chemicals that
activate PKC and flux calcium, and therefore mimic CD3 and CD28 cross linking. We had
seen that in primary Th2 cells GCs were able to reduce IL-13 mRNA transcript levels.
CCRF-CEM cells do not have basal expression of IL-13 thus they had to be activated in
order to produce cytokines. We wanted to assess whether T cell activation would inhibit the
GR from reducing IL-13 mRNA levels. We found that after dexamethasone treatment IL-13
mRNA levels were significantly reduced in activated T cells. However, there was only 30%
reduction of IL-13 mRNA in activated cells compared to the 80% reduction seen in resting
primary Th2 cells.
To assess whether the blunted regulation of IL-13 by GCs was a result of reduced GR
activity we treated CCRF-CEM cells with dexamethasone along with PMA and ionomycin.
As expected, we found that FKBP5 mRNA transcript levels were increased in response to
dexamethasone, but the effect was significantly less in activated cells. This phenomenon was
similar with GR transcript levels, which were higher in resting cells in response to
dexamethasone treatment compared to activated cells. These data suggest that activated Th2
cells are less responsive to GC, due to downregulation of GR signaling genes. This is
significant because regulation of FKBP5 and GR are essential for maintaining GR function.
Reduction of FKBP5 and GR mRNA indicate that there could be a reduction in GR effect.
This makes the IL-13 results more significant because even with reduced activity, the GR
was still able to inhibit IL-13 mRNA expression. If GR activity is reduced we wanted to
assess whether this would affect the dexamethasone-mediated upregulation of CRTh2.
However we found that the downregulation of by T cell activation, could not be reversed by
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dexamethasone treatment [80]. However, whether this is due to effects on CRTh2
transcription rather than reduced GR activity, is possible. Work in our lab has identified that
NFAT binds to the CRTh2 locus upon activation to downregulate mRNA. NFAT-AP-1 sites
have been shown to overlap with GREs, thus preventing the GR from regulating transcription
(Maclean, unpublished).
Previous research has identified that GR signaling can interfere with factors up-regulated in
T cell activation and vice versa [53, 172]. The level of T cell activation versus GR activation
becomes important when trying to understand two competing pathways. With FKBP5 and
GR levels reduced during T cell activation this indicates that the level of activation
outweighs GR signaling. This again becomes evident with the inability of GR to regulate
CRTh2 expression as previously described. Potentially, this points to the fact that GR
resistance may occur from constant T cell activation which is a feature of chronic allergen
exposure. Thus, low dose GCs in patients may not be able to surmount the level of allergen
induced T cell activation, thereby rendering GCs ineffective.

4.5

Conclusion

The data demonstrate that the effect of GCs on Th2 cells is largely dose dependent. Whether
cells are at rest or activated, to promote anti-inflammatory effects of the GR a competitive
dose of GCs is necessary. Clinically, this may translate to prescribing more GCs since
insufficient doses of GCs enhance the potential for Th2 mediated inflammation. Side effects
from GCs are a concern, as long-term treatment can lead to developing cataracts,
osteoporosis and adrenal insufficiency. Interestingly, this work suggests that there may be
side effects from taking low doses that suppress cytokines but are insufficient to induce Th2
cell apoptosis. Insufficient dose of GCs may allow Th2 cells to survive and thrive due to
CRTh2 upregulation. The balance between GCs and Th2 inflammation forces us to rethink
asthma therapy strategies based on patient characteristics (Figure 20). One approach of
asthma therapy could be to measure the drop in Th2 cells as they undergo GC induced
apoptosis. This approach should be coupled with improvements in GC selectivity and
potency due to the side effects many patients experience when taking high doses of the
currently available GCs. Collectively, this study highlights the importance of further work to

51

develop methods for determining a personalized approach for achieving maximum antiinflammatory effects.

Figure 20: The effect of glucocorticosteroids is dose dependent
Our data suggest that the ability of GCs to promote or reduce inflammation is dependent on
dose of GCs. 1) The ability of GCs to increase CRTh2 expression and reduce IL-13 shows
that GCs can inhibit immediate inflammatory effects while enhancing Th2 inflammatory
potential. 2) High dose GCs induces apoptosis in Th2 cells and thereby reduce Th2 mediated
inflammation. 3) Activation of T cells inhibits GC response and thereby shifts the balance
towards increased inflammation.

4.6

Future Direction

GCs function is dependent on dose, which means the strength of GCs is important in
determining the effect. To validate these findings, it would be interesting to compare GCs of
different potencies with their ability to regulate transcription and apoptosis. This will be
directly applicable clinically as although there are guidelines for prescribing doses of GCs,
there are no current guidelines for which inhaled GCs to prescribe.
For this study, we focused on CRTh2 surface expression rather than total protein expression
because surface CRTh2 is the functional protein. One of the downfalls is that because we
assessed surface expression we are still unclear whether mRNA changes at concentrations
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above 0.01µM are reflected by total CRTh2 protein. Determining total protein will also help
identify whether the limiting factor is the ability of cells to transport CRTh2 to the surface.
One major limitation of this study is the lack of functional readout for the increase in CRTh2
at low dose GCs. This increase could have implications in responses following allergen
exposure leading to enhanced cytokines, chemotaxis and/or Th2 cell survival. Pre-treating
Th2 cells with low dose GCs prior to PGD2 treatment may provide evidence of the
deleterious effect of low dose GC.
CRTh2 activation is considered to play a significant role in asthma pathogenesis. The
obvious thought would be to inhibit PGD2 production to reduce inflammation. It may not be
that simple since there is an asthma phenotype called aspirin sensitive asthma that is
mediated primarily by leukotrienes [179]. Since arachidonic acid is a precursor for both
PGD2 and leukotrienes [180], when aspirin inhibits the COX enzymes the production of
PGD2 is reduced leading to increased production of leukotrienes [180]. Therefore, inhibition
of PGD2 production may be an effective approach for reducing inflammation, but would have
to be tested in patients that do not exhibit aspirin sensitivity.
This study focuses on the balance between GC signaling and Th2 inflammation. Although
severity of asthma has been correlated with PGD2 and percentage of Th2 cells, this does not
address why severe asthmatics have elevated inflammation in the first place. This could be
related to GC effect on Th2 cell differentiation. We have seen that GCs promote
differentiation of Tregs, whether this holds true for Th2 cells remains to be seen. Previous
research has shown that CD4+ T cells pretreated with GCs under differentiating conditions
enhances type 2 cytokine release. Thus, although we have shown GCs can reduce type 2
cytokines, GC treatment prior to the production of cytokines may help prime the cells for an
enhanced cytokine release. This could further provide evidence of the effect of low dose GCs
in not only sustaining but developing Th2 cells.
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